(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of -7.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.18%.
Lexicon Pharmaceuticals's revenue in 2026 is $70,864,000.On average, 7 Wall Street analysts forecast LXRX's revenue for 2026 to be $7,770,190,576, with the lowest LXRX revenue forecast at $0, and the highest LXRX revenue forecast at $13,742,647,882. On average, 6 Wall Street analysts forecast LXRX's revenue for 2027 to be $9,492,336,920, with the lowest LXRX revenue forecast at $2,241,443,058, and the highest LXRX revenue forecast at $22,703,332,533.
In 2028, LXRX is forecast to generate $22,569,238,420 in revenue, with the lowest revenue forecast at $2,777,819,510 and the highest revenue forecast at $47,278,168,268.